MARKET

IOVA

IOVA

Iovance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.15
+0.29
+0.94%
Closed 19:12 08/06 EDT
OPEN
30.90
PREV CLOSE
30.86
HIGH
31.59
LOW
30.57
VOLUME
880.49K
TURNOVER
--
52 WEEK HIGH
41.49
52 WEEK LOW
17.67
MARKET CAP
4.56B
P/E (TTM)
-16.9579
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IOVA stock price target is 47.08 with a high estimate of 65.00 and a low estimate of 38.00.

EPS

IOVA News

More
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer StudySAN CARLOS, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapie
GlobeNewswire · 13h ago
Lion Biotechnologies Reaches 80-Plus Relative Strength Rating Benchmark
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
Investor's Business Daily · 2d ago
Iovance Biotherapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
SAN CARLOS, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its second quarter 2020 financial results on Thursday, Augu
GlobeNewswire · 07/23 11:30
Steven Cohen Homes in on Otonomy by Expanding Stake
GuruFocus.com · 07/15 18:15
Were Hedge Funds Right About Iovance Biotherapeutics, Inc. (IOVA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 07/14 16:49
Is Iovance Biotherapeutics a Buy?
Motley Fool · 07/01 12:11
Adding One More Dimension In Solid Tumor Therapy - Iovance Biotherapeutics
Seeking Alpha - Article · 06/24 15:38
Iovance Biotherapeutics Option Alert: Sep 18 $35 Calls Sweep (13) near the Ask: 410 @ $3.201 vs 3488 OI; Earnings 7/30 After Close [est] Ref=$31.55
Benzinga · 06/23 14:18

Industry

Biotechnology & Medical Research
-0.96%
Pharmaceuticals & Medical Research
-0.46%

Hot Stocks

Symbol
Price
%Change

About IOVA

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, it is investigating TIL therapy and peripheral blood lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer and chronic lymphocytic leukemia.
More

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.